MeSH term
Frequency | Condition_Probility | Animals | 16 | 0.0 |
Binding, Competitive | 4 | 0.0 |
CHO Cells | 2 | 0.0 |
Hamsters | 5 | 0.0 |
Humans | 65 | 0.0 |
Male | 18 | 0.0 |
Rats | 4 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Receptor, Muscarinic M1 | 2 | 8.0 |
Receptor, Muscarinic M4 | 2 | 66.0 |
Structure-Activity Relationship | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 46 | 0.0 |
Cells, Cultured | 3 | 0.0 |
Comparative Study | 7 | 0.0 |
Iodine Radioisotopes | 2 | 0.0 |
Kinetics | 4 | 0.0 |
Mice | 10 | 0.0 |
Receptors, Melatonin | 2 | 12.0 |
Species Specificity | 2 | 0.0 |
Temperature | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Mutation | 2 | 0.0 |
Cell Line | 14 | 0.0 |
In Vitro | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Antibodies, Monoclonal/*immunology | 5 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 6 | 0.0 |
Epitopes/immunology | 4 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Adult | 12 | 0.0 |
Aged | 7 | 0.0 |
Middle Aged | 10 | 0.0 |
Multiple Myeloma/*metabolism/pathology | 2 | 10.0 |
Antibodies, Monoclonal/*pharmacology | 2 | 1.0 |
Base Sequence | 6 | 0.0 |
Female | 16 | 0.0 |
Molecular Sequence Data | 5 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 20 | 0.0 |
Antigen-Antibody Reactions | 4 | 1.0 |
Cell Cycle | 2 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Lymphocyte Culture Test, Mixed | 2 | 0.0 |
Antibody Specificity | 3 | 0.0 |
Antigens, CD45 | 2 | 0.0 |
Epitopes | 8 | 0.0 |
Molecular Weight | 2 | 0.0 |
Cytochrome c Group/genetics | 2 | 33.0 |
Hela Cells | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
B-Lymphocytes/immunology | 10 | 1.0 |
Amino Acid Sequence | 4 | 0.0 |
Genotype | 3 | 0.0 |
HLA-DR Antigens | 26 | 7.0 |
HLA-DR4 Antigen | 7 | 11.0 |
HLA-DR7 Antigen | 5 | 38.0 |
Antibodies, Monoclonal/diagnostic use | 3 | 0.0 |
Antigen-Presenting Cells/immunology | 2 | 0.0 |
HLA Antigens/analysis | 4 | 1.0 |
HLA-DP Antigens | 3 | 13.0 |
Histocompatibility Antigens Class II/*immunology | 7 | 4.0 |
T-Lymphocytes/*immunology | 4 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Genes, Structural | 2 | 0.0 |
Histocompatibility Antigens Class II/*genetics | 5 | 2.0 |
Linkage (Genetics) | 4 | 0.0 |
*Major Histocompatibility Complex | 4 | 1.0 |
Polymorphism, Genetic | 7 | 0.0 |
HLA-DQ Antigens | 4 | 12.0 |
HLA Antigens/immunology | 4 | 2.0 |
Antibodies, Monoclonal | 5 | 0.0 |
Epitopes/analysis | 3 | 1.0 |
Histocompatibility Antigens Class II/*analysis/immunology | 3 | 37.0 |
Homozygote | 8 | 0.0 |
Lymphocyte Activation | 7 | 0.0 |
Lymphocytes/*immunology | 2 | 0.0 |
Adolescent | 6 | 0.0 |
Child | 5 | 0.0 |
Child, Preschool | 4 | 0.0 |
China/ethnology | 2 | 1.0 |
HLA-DR3 Antigen | 3 | 7.0 |
Infant | 2 | 0.0 |
Singapore | 2 | 4.0 |
HLA Antigens/*analysis | 3 | 0.0 |
Histocompatibility Antigens Class II/*analysis | 6 | 5.0 |
Epitopes/*analysis | 2 | 1.0 |
Histocompatibility Antigens Class II/immunology | 3 | 1.0 |
Monocytes/immunology | 2 | 0.0 |
*Genes, MHC Class II | 6 | 1.0 |
Phenotype | 6 | 0.0 |
B-Lymphocytes/*immunology | 4 | 0.0 |
Precipitation | 3 | 1.0 |
*Histocompatibility Testing | 3 | 1.0 |
Gene Frequency | 5 | 0.0 |
HLA Antigens/genetics | 3 | 0.0 |
HLA-A Antigens | 5 | 1.0 |
HLA-B Antigens | 6 | 1.0 |
Japan | 7 | 0.0 |
Risk | 2 | 0.0 |
Antibodies, Monoclonal/immunology | 4 | 0.0 |
Genes, MHC Class II | 8 | 3.0 |
Glomerulonephritis/genetics/*immunology | 2 | 33.0 |
HLA Antigens/*genetics | 3 | 0.0 |
Histocompatibility Testing | 5 | 0.0 |
Prospective Studies | 2 | 0.0 |
Histocompatibility Antigens Class II/analysis | 2 | 1.0 |
Clone Cells/immunology | 2 | 1.0 |
